9. Fate Therapeutics Inc. (NASDAQ:FATE)
Off-the-Shelf Cell Therapy Targets a Manufacturing Breakthrough
Fate Therapeutics, Inc. (NASDAQ: FATE) is developing cell therapies derived from induced pluripotent stem cells, or iPSCs. These cells provide a starting material for engineered treatments that can be manufactured and held in inventory. The ambition is to make advanced cellular medicines more readily available without producing a separate treatment from each patient’s own cells.
Its development strategy increasingly includes autoimmune diseases. In August 2026, the business reported that the first patient had received FT819 in RECLAIM-LN, a Phase 2 potentially registrational study in lupus nephritis. The patient received treatment in an outpatient setting and was discharged the same day. That is an operational milestone, although one patient’s experience cannot establish the broader treatment profile.
Cash, cash equivalents, and investments totaled $153.8 million at June 30. Management expected that funding to support operations into 2028. Second-quarter operating expenses were $33.2 million, underscoring the continuing expense of advancing a cell therapy pipeline.
Ranking Rationale
The No. 9 position recognizes the potential manufacturing advantages of an off-the-shelf platform and progress in autoimmune disease. Clinical uncertainty, treatment complexity, and the work required to establish durable patient benefits keep this a speculative biotechnology investment.
